[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342184-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342184-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","lymphocyte-activation-gene-3-in-cancer-immunotherapy-function-prognostic-biomarker-and-therapeutic-potentials","Lymphocyte-activation gene 3 in cancer immunotherapy - function, prognostic biomarker and therapeutic potentials","","Lymphocyte-activation gene 3 (LAG-3) functions as an immune checkpoint that regulates anti-tumor immunity by delivering inhibitory signals to T cells. This review explains how LAG-3 suppresses immune responses, details its interactions with ligands, and evaluates its role in immune regulation within the tumor microenvironment. It further summarizes evidence for LAG-3 as a prognostic biomarker across cancers and reviews therapeutic strategies targeting LAG-3, including monoclonal antibodies, small-molecule inhibitors, and CAR T cells.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/lymphocyte-activation-gene-3-in-cancer-immunotherapy-function-prognostic-biomarker-and-therapeutic-potentials/342184/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/lymphocyte-activation-gene-3-in-cancer-immunotherapy-function-prognostic-biomarker-and-therapeutic-potentials/342184.png","ImageObject",300,407,{"name":42,"@type":43},"Clementine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does LAG-3 play in cancer immune regulation?","Question",{"text":63,"@type":64},"LAG-3 acts as an inhibitory immune checkpoint that suppresses T cell activation and proliferation. Its inhibitory effect contributes to reduced anti-tumor immunity and supports tumor progression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does LAG-3 relate to immune checkpoint inhibitors and treatment outcomes?",{"text":68,"@type":64},"The review places LAG-3 within the broader landscape of immune checkpoint inhibitors, noting that many patients respond poorly and can develop immune-related adverse effects. It highlights LAG-3 as an additional checkpoint with therapeutic potential to improve outcomes.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is LAG-3 considered a prognostic biomarker?",{"text":72,"@type":64},"High LAG-3 expression in multiple tumors is associated with cancer patient prognosis. The review concludes it may serve as an independent prognostic biomarker for tumor treatment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342184,1790197728,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","TYPE Review  \nPUBLISHED 26 November 2024 DOI 10.3389/fimmu.2024.1501613  \nOPEN ACCESS  \nEDITED BY  \nJesse Haramati,  \nUniversity of Guadalajara, Mexico  \nREVIEWED BY  \nGraham Robert Leggatt, The University of Queensland, Australia Vanaja Konduri,  \nBaylor College of Medicine, United States  \n*CORRESPONDENCE  \nEyad Elkord  \n [eyad.elkord@xjtlu.edu.cn](eyad.elkord@xjtlu.edu.cn);  \n [eyad.elkord@liverpool.ac.uk](eyad.elkord@liverpool.ac.uk)  \nRECEIVED 25 September 2024  \nACCEPTED 07 November 2024  \nPUBLISHED 26 November 2024  \nCITATION  \nRen K, Hamdy H, Meyiah A and Elkord E (2024) Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials.  \nFront. Immunol. 15:1501613 .  \ndoi: 10.3389/fimmu.2024.1501613  \nCOPYRIGHT  \n© 2024 Ren, Hamdy, Meyiah and Elkord. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nLymphocyte-activation gene 3 in cancer immunotherapy:  \nfunction, prognostic biomarker and therapeutic potentials  \nKe Ren 1, Hayam Hamdy 2, Abdo Meyiah 1 and Eyad Elkord 1,3,4*  \n1 Department of Biosciences and Bioinformatics, School of Science, Suzhou Municipal Key Lab in Biomedical Sciences and Translational Immunology, Xi ’an Jiaotong-Liverpool University, Suzhou, Jiangsu, China, 2 Department of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, New Valley University, New Valley, Egypt, 3College of Health Sciences, Abu Dhabi University, Abu Dhabi, United Arab Emirates, 4 Biomedical Research Center, School of Science, Engineering and Environment, University of Salford, Manchester, United Kingdom  \nLymphocyte-activation gene 3 (LAG-3) has emerged as a key immune checkpoint regulating immune responses in the context of cancer . The inhibitory effect of LAG-3-expressing T cells contributes to suppressing antitumor immunity and promoting tumor progression. This review discusses the function of LAG-3 in immune suppression, its interactions with ligands, and its potential as a prognostic biomarker for cancers. We also explore therapeutic strategies targeting LAG-3, including monoclonal antibodies, small molecule inhibitors, and CAR T cells. This review summarizes the current preclinical and clinical studies on LAG-3, highlighting the potential of therapeutic regimens targeting LAG-3 to enhance antitumor immunity and improve patients ’outcomes. Further studies are needed to fully elucidate the mechanism of action of LAG-3 and optimize its application in tumor therapy.  \nKEYWORDS  \nbiomarker, T cells, LAG-3, immune checkpoint, cancer  \n1 Introduction  \nDespite signiﬁcant advances in cancer treatment, cancer remains a leading cause of human death (1) . Traditional treatments, such as chemotherapy and radiotherapy, often have limited therapeutic effects due to adverse reactions and acquired drug resistance (2) . Therefore, new treatment options are constantly explored, among which immune checkpoint inhibitors (ICIs) have brought breakthroughs in tumor treatment strategies.  \nICIs enhance anti-tumor immune responses by blocking immune checkpoint proteins that inhibit T cell function, such as cytotoxic T lymphocyte antigen 4 (CTLA-4) and  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nprogrammed death protein 1 (PD-1) (1). In March 2011, the US Food and Drug Administration (FDA) approved ipilimumab (Yervoy®), the ﬁrst anti-CTLA-4 monoclonal antibody (mAb), for the treatment of advanced melanoma (3–5) . Subsequently, PD-1 and PD-L1 inhibitors were approved and showed signiﬁcant clinical effects in various cancers, prolonging patients’ progression-free survival (","cbCainvL6og7ewaU","https://ap.wps.com/l/cbCainvL6og7ewaU","pdf",2596710,12,"English","# Introduction\n## Immune checkpoint inhibitors and limitations\n## LAG-3 as an emerging immune checkpoint\n# LAG-3 interactions and therapeutic targeting\n## Co-expression with other checkpoints and T cell exhaustion\n## Prognostic value and therapeutic strategies","[{\"question\":\"What role does LAG-3 play in cancer immune regulation?\",\"answer\":\"LAG-3 acts as an inhibitory immune checkpoint that suppresses T cell activation and proliferation. Its inhibitory effect contributes to reduced anti-tumor immunity and supports tumor progression.\"},{\"question\":\"How does LAG-3 relate to immune checkpoint inhibitors and treatment outcomes?\",\"answer\":\"The review places LAG-3 within the broader landscape of immune checkpoint inhibitors, noting that many patients respond poorly and can develop immune-related adverse effects. It highlights LAG-3 as an additional checkpoint with therapeutic potential to improve outcomes.\"},{\"question\":\"Why is LAG-3 considered a prognostic biomarker?\",\"answer\":\"High LAG-3 expression in multiple tumors is associated with cancer patient prognosis. The review concludes it may serve as an independent prognostic biomarker for tumor treatment.\"}]","Lymphocyte-activation gene 3 in cancer immunotherapy - function, prognostic biomarker and therapeutic potentials | PDF",1790045726,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34a79cebcc35847c6734e43f266cdcfd.webp",983,1389,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc6a8806f0a9a87558d376971dc79723.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4012c286d034ae405c60f8ff5ca1669.webp",981,1386,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d6bd217d6f50c5915a87ee2d4c1f1c02.webp",980,1385]